Advances in lipid-based nanocarriers for breast cancer metastasis treatment

Abstract

Breast cancer (BC) is the most common cancer affecting women worldwide, with over 2 million women diagnosed every year, and close to 8 million women currently alive following a diagnosis of BC in the last 5-years. The side effects such as chemodrug toxicity to healthy tissues and drug resistance severely affect the quality of life of BC patients. To overcome these limitations, many efforts have been made to develop nanomaterial-based drug delivery systems. Among these nanocarriers, lipid-based delivery platforms represented one of the most successful candidates for cancer therapy, improving the safety profile and therapeutic efficacy of encapsulated drugs. In this review we will mainly discuss and summarize the recent advances in such delivery systems for BC metastasis treatment, with a particular focus on targeting the common metastatic sites in bone, brain and lung. We will also provide our perspectives on lipid-based nanocarrier development for future clinical translation.

Enhancing Breast Cancer Therapy: Nanocarrier-Based Targeted Drug Delivery

“…Our confocal and flow cytometry experiments demonstrated that this may be caused by the interaction of NC, NLC, and NE lipid nanocarriers within MDA-MB-231 and MCF-7 cells. To get around these issues, the usage of nanocarriers is being researched.79 [92]. Researchers describe a novel class of hybrid nucleoside-lipid-based sorafenibbased nanoparticles.…”

“…The outcomes illustrate the utilization of therapeutically relevant radiation doses to facilitate concurrent receptor-mediated enhanced chemotherapeutic administration, while minimizing systemic toxicity. 92,105,106,107,108 .…”